Growth hormone shows promise in shrinking HIV's hiding spots
NCT ID NCT03091374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving recombinant human growth hormone for 48 weeks could reduce the hidden HIV reservoir in people already on successful antiretroviral therapy (ART). The goal was to move toward a 'functional cure' where the body can control the virus without lifelong medication. Twenty-two HIV-positive adults with undetectable viral loads took part. The main focus was on safety and measuring changes in the size of the viral reservoir.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROWTH HORMONE TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mcgill University Health Center
Montreal, Quebec, H4A 3J1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking groups could shield HIV-Positive latino men from heart disease
- Friends helping friends: a novel social-network strategy to boost HIV prevention
- Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
- Could HIV and age weaken vaccine protection? study investigates
- Massive HIV database could unlock secrets of Long-Term health
- Can couples counseling curb HIV? new study tests dyadic approach in south africa